相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation
Eytan M. Stein
CLINICAL CANCER RESEARCH (2016)
Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients
Patryk Gorniak et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
C. D. DiNardo et al.
LEUKEMIA (2016)
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2016)
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
Owen Clark et al.
CLINICAL CANCER RESEARCH (2016)
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model
Fang Wang et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2016)
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
A. Chaturvedi et al.
LEUKEMIA (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia
Caroline E. Sloan et al.
PLOS ONE (2016)
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
Ashkan Emadi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
IDH2 inhibition in AML: Finally progress?
Eytan M. Stein
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2015)
Getting a handle on hereditary CEBPA mutations
Courtney D. DiNardo
BLOOD (2015)
Living with CML: is death no longer the end (point)?
Deborah L. White et al.
BLOOD (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Current challenges in clinical development of targeted therapies: the case of acute myeloid leukemia
Elihu Estey et al.
BLOOD (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders
Sadudee Chotirat et al.
BLOOD CELLS MOLECULES AND DISEASES (2015)
Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients
Salah Aref et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Enigmas of IDH mutations in hematology/oncology
Michael Heuser et al.
EXPERIMENTAL HEMATOLOGY (2015)
Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Mia Y. Platt et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Inhibition of mutant IDH1 in acute myeloid leukaemia
Farhat Yaqub
LANCET ONCOLOGY (2015)
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
R. J. Molenaar et al.
LEUKEMIA (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
Luyuan Li et al.
PLOS ONE (2015)
Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia
Amir T. Fathi et al.
SEMINARS IN HEMATOLOGY (2015)
Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis
Thomas McKerrell et al.
CELL REPORTS (2015)
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Andrew Kernytsky et al.
BLOOD (2015)
Red cells in post-genomic era: impact of personalized medicine in the treatment of anemias
Achille Iolascon et al.
HAEMATOLOGICA (2015)
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
Chien-Chin Lin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation
Shunichiro Yamaguchi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations
Ashkan Emadi et al.
EXPERIMENTAL HEMATOLOGY (2014)
Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Maxime Janin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
A. P. Im et al.
LEUKEMIA (2014)
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
Courtney D. DiNardo et al.
LEUKEMIA & LYMPHOMA (2014)
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush et al.
NATURE (2014)
Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis
Jie Jin et al.
PLOS ONE (2014)
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
M. Ryan Corces-Zimmerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia
Raajit Rampal et al.
CELL REPORTS (2014)
Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia
Kerstin Willander et al.
BIOMARKER RESEARCH (2014)
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Omar Abdel-Wahab et al.
BLOOD (2013)
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Anuhar Chaturvedi et al.
BLOOD (2013)
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2013)
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Genglin Jin et al.
CANCER RESEARCH (2013)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Steven M. Chan et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization
Patrick S. Ward et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Jiang-Han Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Julie-Aurore Losman et al.
SCIENCE (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2012)
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Amir T. Fathi et al.
BLOOD (2012)
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
Terra L. Lasho et al.
BLOOD (2012)
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin
Farhad Ravandi et al.
CANCER (2012)
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Hui Yang et al.
CLINICAL CANCER RESEARCH (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
Sadudee Chotirat et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients
M. M. Patnaik et al.
LEUKEMIA (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Acute Myeloid Leukemia With IDH1 or IDH2 Mutation Frequency and Clinicopathologic Features
Keyur P. Patel et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Nicolas Boissel et al.
BLOOD (2011)
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Claire L. Green et al.
BLOOD (2011)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Rasheduzzaman Chowdhury et al.
EMBO REPORTS (2011)
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia
Isam Abdel-Karim et al.
INVESTIGATIONAL NEW DRUGS (2011)
Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia An Algorithmic Approach Using High-Resolution Melting Curve Analysis
Keyur P. Patel et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
W-C Chou et al.
LEUKEMIA (2011)
Metabolism unhinged: IDH mutations in cancer
John R. Prensner et al.
NATURE MEDICINE (2011)
Genetics of Myelodysplastic Syndromes: New Insights
Timothy Graubert et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Regulation of cancer cell metabolism
Rob A. Cairns et al.
NATURE REVIEWS CANCER (2011)
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
Susanne Schnittger et al.
BLOOD (2010)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
Saman Abbas et al.
BLOOD (2010)
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2010)
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation
Wen-Chien Chou et al.
BLOOD (2010)
IDH1 and IDH2: Not Your Typical Oncogenes
Zachary J. Reitman et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
Felicitas Thol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Nicolas Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
Katharina Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies
Craig Horbinski et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
A. Pardanani et al.
LEUKEMIA (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
Pierre Fenaux et al.
LEUKEMIA RESEARCH (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
分享论文
